His primary scientific interests are in Dipeptidyl peptidase, Internal medicine, Endocrinology, Biochemistry and Insulin. Dipeptidyl peptidase is a subfield of Enzyme that Hans-Ulrich Demuth explores. His research in Internal medicine intersects with topics in Diabetes mellitus, Incretin, Glucagon-like peptide-1, Type 2 diabetes and In vivo.
His studies deal with areas such as Receptor and Biological activity, In vitro as well as Endocrinology. Hans-Ulrich Demuth combines subjects such as Gastric inhibitory polypeptide and Peptide with his study of Receptor. The Biochemistry study combines topics in areas such as Cell culture and Dipeptidyl peptidase-4.
His primary areas of investigation include Biochemistry, Dipeptidyl peptidase, Internal medicine, Endocrinology and Enzyme. His study in Biochemistry is interdisciplinary in nature, drawing from both Chromatography and In vivo. His work deals with themes such as Incretin, Blood sugar, Dipeptidyl peptidase-4, Pharmacology and Effector, which intersect with Dipeptidyl peptidase.
His work carried out in the field of Internal medicine brings together such families of science as Diabetes mellitus and Type 2 diabetes. His Endocrinology research includes themes of Receptor, Genetically modified mouse and Neuropeptide Y receptor. In his research on the topic of Enzyme, Amino acid, Active site, Residue, Serine and Proline is strongly related with Stereochemistry.
Hans-Ulrich Demuth mainly focuses on Biochemistry, Cell biology, Amyloid, Internal medicine and Genetically modified mouse. His Biochemistry research focuses on In vivo and how it connects with In vitro and Peptide. His biological study spans a wide range of topics, including Endocrinology, Cognition and Mechanism of action.
His Genetically modified mouse study combines topics in areas such as Gliosis and Amyloid precursor protein. The concepts of his Exopeptidase activity study are interwoven with issues in Dipeptidyl peptidase and Protein precursor. In his research, Glutamate receptor and Dipeptidyl peptidase-4 is intimately related to Cleavage, which falls under the overarching field of Dipeptidyl peptidase.
His primary areas of study are Biochemistry, Alzheimer's disease, In vivo, Cell biology and Internal medicine. His study in the field of Peptide, Enzyme, Signal transduction and Fibril is also linked to topics like Lead structure. His Alzheimer's disease research integrates issues from Immunology, Gene isoform, Monoclonal antibody and Immunotherapy.
His In vivo study incorporates themes from In vitro and Amyloid. His studies in Internal medicine integrate themes in fields like Serine protease, Endocrinology and Pathology. When carried out as part of a general Endocrinology research project, his work on Dipeptidyl peptidase-4 is frequently linked to work in Population, therefore connecting diverse disciplines of study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Dipeptidyl Peptidase IV Inhibitor Treatment Stimulates β-Cell Survival and Islet Neogenesis in Streptozotocin-Induced Diabetic Rats
J. Andrew Pospisilik;Jennifer Martin;Timothy Doty;Jan A. Ehses.
Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide
Raymond A Pederson;Heather A White;Dagmar Schlenzig;Robert P Pauly.
Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β
Justin M. Nussbaum;Stephan Schilling;Holger Cynis;Antonia Silva.
The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism
Michael Engel;Torsten Hoffmann;Leona Wagner;Michael Wermann.
Proceedings of the National Academy of Sciences of the United States of America (2003)
Long-Term Treatment With the Dipeptidyl Peptidase IV Inhibitor P32/98 Causes Sustained Improvements in Glucose Tolerance, Insulin Sensitivity, Hyperinsulinemia, and β-Cell Glucose Responsiveness in VDF (fa/fa) Zucker Rats
J. A. Pospisilik;S. G. Stafford;H.-U. Demuth;R. Brownsey.
Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology.
Stephan Schilling;Ulrike Zeitschel;Torsten Hoffmann;Ulrich Heiser.
Nature Medicine (2008)
Type 2 diabetes—Therapy with dipeptidyl peptidase IV inhibitors
Hans-Ulrich Demuth;Christopher H.S. McIntosh;Raymond A. Pederson.
Biochimica et Biophysica Acta (2005)
On the seeding and oligomerization of pGlu-amyloid peptides (in vitro).
Stephan Schilling;Thomas Lauber;Michael Schaupp;Susanne Manhart.
Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Dermusy H-U;Rosh F;Schmider J.
Glucose-Dependent Insulinotropic Polypeptide Promotes β-(INS-1) Cell Survival via Cyclic Adenosine Monophosphate-Mediated Caspase-3 Inhibition and Regulation of p38 Mitogen-Activated Protein Kinase
Jan A. Ehses;Vanbric R. Casilla;Tim Doty;J. Andrew Pospisilik.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: